Last reviewed · How we verify
NCT03660462: HiFe
Iron Bioavailability of High Surface Area Ferric Phosphate
NA trial testing FeSO4 fortified rice test meal in Iron-deficiency in 18 participants. Completed in 19 July 2019.
19 June 2019
Quick facts
| Lead sponsor | Swiss Federal Institute of Technology |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 21 November 2018 |
| Primary completion | 19 June 2019 |
| Estimated completion | 19 July 2019 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- FeSO4 fortified rice test meal
- FePO4 fortified rice test meal
- HiFePO4 1 fortified rice test meal
- HiFePO4 2 fortified rice test meal
Conditions studied
- Iron-deficiency — all drugs for Iron-deficiency →
Sponsor
Swiss Federal Institute of Technology
Who can join
Adults 18 to 49, female only, with Iron-deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to compare iron absorption of high surface area ferric phosphate with that of ferrous sulfate and bulk ferric phosphate in a rice-based meal in non-pregnant women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03660462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Iron-deficiency
Currently open trials in the same condition.
- NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
- NCT06270498 — Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure · Phase 4 · recruiting
- NCT05913414 — Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT05340465 — Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants · Phase 2 · recruiting
- NCT07083492 — Non-invasive Detection of Iron Deficiency in Obstetrics · recruiting
Other Swiss Federal Institute of Technology trials
Trials by the same sponsor.
- NCT07182734 — Feasibility of Unsupervised Therapy After Neurological or Orthopaedical Injury in the Home Setting With a Hand Rehabilit · NA · not yet recruiting
- NCT06725784 — Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation with Different Levels of Supervision · NA · recruiting
- NCT06851130 — Assessing the Immediate Increase in Serum Ferritin After Oral Iron Doses: an Experimental Study in Iron-deficient Women · NA · recruiting
- NCT06149975 — Feasibility of a Motor-cognitive Training Program in Patients With Traumatic Brain Injury · NA · completed
- NCT06116669 — Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03660462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Swiss Federal Institute of Technology
- Last refreshed: 14 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03660462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing